

## DNA methylation/hydroxymethylation in melanoma

Siqi Fu<sup>1,\*</sup>, Haijing Wu<sup>1,\*</sup>, Huiming Zhang<sup>1</sup>, Christine G. Lian<sup>2</sup> and Qianjin Lu<sup>1</sup>

<sup>1</sup>Department of Dermatology, Second Xiangya Hospital, Central South University, Hunan Key Laboratory of Medical Epigenomics, Changsha, Hunan, China

<sup>2</sup>Program in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

\*These authors have contributed equally to this work

Correspondence to: Lu Qianjin, email: qianlu5860@gmail.com

Keywords: melanoma, 5-hmC, 5-mC, epigenetic therapy, TET

Received: March 02, 2017

Accepted: May 03, 2017

Published: May 30, 2017

Copyright: Fu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### ABSTRACT

**Melanoma is a malignant tumor of melanocytes and is considered to be the most aggressive cancer among all skin diseases. The pathogenesis of melanoma has not been well documented, which may restrict the research and development of biomarkers and therapies. To date, several genetic and epigenetic factors have been identified as contributing to the development and progression of melanoma. Besides the findings on genetic susceptibilities, the recent progress in epigenetic studies has revealed that loss of the DNA hydroxymethylation mark, 5-hydroxymethylcytosine (5-hmC), along with high levels of DNA methylation at promoter regions of several tumor suppressor genes in melanoma, may serve as biomarkers for melanoma. Moreover, 5-Aza-2'-deoxycytidine, an epigenetic modifier causing DNA demethylation, and ten-eleven translocation family dioxygenase (TET), which catalyzes the generation of 5-hmC, demonstrate therapeutic potential in melanoma treatment. In this review, we will summarize the latest progress in research on DNA methylation/hydroxymethylation in melanoma, and we will discuss and provide insight for epigenetic biomarkers and therapies for melanoma. Particularly, we will discuss the role of DNA hydroxymethylation in melanoma infiltrating immune cells, which may also serve as a potential target for melanoma treatment.**

### INTRODUCTION

Melanoma is the most aggressive form of skin cancer, in which metastasis is the most common cause of death in patients. Melanoma commonly arises from cutaneous melanocytes, but it can also occur on mucosal surfaces such as the oral cavity, gastrointestinal sites, and genital mucosa as well as the uveal tract of the eye and leptomeninges. The pathogenesis of melanoma has not been well elucidated; however, several risk factors have been revealed to be associated with melanoma, such as hair color [1], skin phototype, numerous nevi, ultraviolet exposure [2], and family history of melanoma [3]. Therefore, genetics and environmental factor-induced epigenetic alterations have been found to contribute to

melanoma. In recent decades, billions of dollars have been invested into the research on genetic susceptibilities to melanoma and development of genetic therapies. Thus far, thousands of mutational events have been observed in the melanoma genome, and the melanoma genome has been revealed to be characterized by high frequencies of mutations carrying a signature of ultraviolet-B radiation [4-5]. *BRAF* is the gene most frequently mutated (50-70%) in melanoma, and *BRAF*<sup>V600E</sup> is the most common mutation, which is usually found in benign nevi [6]. Despite the advances in gene targeting therapy, the development of inhibitors of mutant *BRAF* kinase, for example, as therapeutic agents, is stagnant due to resistance to the therapy [7]. In addition, variations in DNA sequence alone cannot completely explain

the biological differences that separate benign nevi from melanoma. Therefore, increasing attention is being focused on the participation of epigenetic events.

Epigenetics refers to the study of potentially heritable changes in gene expression and function that do not involve alterations of the original nucleotide sequence of DNA. Epigenetic modifications are primarily comprised of DNA methylation, histone modification, and microRNA (miRNA)-mediated and long non-coding RNA (lncRNA)-mediated regulation. These epigenetic mechanisms ultimately determine whether genes are expressed or silenced; therefore, these epigenetic mechanisms play critical roles in various life processes such as cell differentiation, growth, development, aging and immune response [8]. Epigenetics provides an explanation for how environmental factors contribute to our individual phenotype as well as an explanation for susceptibilities to certain diseases such as cancer. In addition, epigenetic status may be more easily manipulated, compared to gene therapies, rendering epigenetic modifications more therapeutically reversible. Therefore, in this review, we will summarize the latest progress made in research on epigenetic modifications, especially DNA methylation/hydroxymethylation, in melanoma, and we will discuss their potential applications as biomarkers and therapeutic strategies for personalized treatment.

## DNA METHYLATION AND HYDROXYMETHYLATION

DNA methylation is a relatively stable and heritable epigenetic mark in several eukaryotic organisms. It is a biochemical process in which a methyl group is added to a cytosine or adenine at the 5-position on the pyrimidine ring of the methyl group where the DNA base thymine is located, converting cytosine to methylcytosine [9]. The CpG dinucleotides tend to cluster in regions called CpG islands, defined as regions of more than 200 bases with a G + C

content of at least 50% and a ratio of observed to statistically expected CpG frequencies of at least 60%. Approximately 60% of gene promoters are associated with CpG islands and are normally unmethylated, although some of them (approximately 6%) become methylated in a tissue-specific manner during early development or in differentiated tissues [10]. This finding may explain why all cells in an organism share the same genetic information, but they show different phenotypes. In general, CpG island methylation is associated with gene silencing. DNA methylation serves as a mark that indicates repression of gene expression; therefore, it is involved in several biological processes, such as cell differentiation and proliferation. DNA methylation inhibits gene expression by various mechanisms. Methyl-CpG-binding domain (MBD) proteins, for example, can be recruited by methylated DNA; in turn, MBD family members recruit histone modifying and chromatin-remodeling complexes to the methylated sites [11]. Moreover, DNA methylation can directly inhibit transcription by precluding the recruitment of DNA-binding proteins to their target sites [12]. However, DNA methylation does not occur exclusively at CpG islands; it may also occur at CpG island shores, which refer to regions of lower densities of CpG that lie close to CpG islands and are associated with transcriptional inactivation (Figure 1). Most tissue-specific DNA methylation occurs not at CpG islands but at CpG island shores [13]. In mammalian cells, DNA methylation is restricted to regions of CpG islands, which are typically present in promoter regions [14] (Figure 2). The process of DNA methylation is mediated by methyltransferases, such as DNMT1, DNMT3a, and DNMT3b, and each of them displays different functional capacities. For example, DNMT1 maintains methylation status during cell replication, whereas DNMT3a and 3b usually induce de novo methylation [15].

In contrast, DNA demethylation is a process that occurs passively, especially by the programmed failure




Figure 1: The CpG islands and CpG island shores.

of transmission of methylation patterns during a round of cell division, and re-activates or re-expresses silenced genes [16]. Unlike DNA methylation, DNA demethylation has been less studied, and active DNA demethylation in mammals has been recognized only recently. This process occurs through the sequential iterative oxidation of the methyl group of 5-mC and removal of the final modified group by the actions of thymine DNA glycosylase (TDG) as well as the base excision repair pathway to yield cytosine from 5-mC [16]. Oxidation of 5-mC to 5-hydroxymethylcytosine 5-hmC is the first and most

important step of this reaction, which is mediated by the TET family dioxygenase enzymes, including TET1, TET2 and TET3 [17]. 5-hmC is the most abundant intermediate of the active DNA demethylation process and acts as a positive transcriptional regulator in normal development and cancer [18–19], and its levels are directly correlated with the levels of differentiation in a wide variety of human tissues [20]. All three TETs can further oxidize 5-hmC to 5-formylcytosine (5-fC) and 5-carboxylcytosine (5-CaC), resulting in tissue levels in the order of 5-mC>5-hmC>5-fC>5-CaC [21]. Meanwhile, both formylcytosine and carboxylcytosine




Figure 2: How DNA methylation regulates transcription.




Figure 3: The cycle of DNA methylation and demethylation.

can be excised by TDG, which triggers subsequent base excision repair (BER), indicating a potential role for active demethylation [19, 22] (Figure 3).

Generally, 5-hmC levels are significantly lower and vary greatly depending on the cell type (0.1-0.7% of total cytosine) compared to the relatively constant levels of 5-mC in somatic tissues (3-4% of total cytosine) [23-24]. The three TET family proteins vary in levels in different cell types. For example, TET1 and TET2 are highly expressed by embryonic stem cells and in early embryogenesis, and their levels decrease when cells exit pluripotency and undergo differentiation. TET2 is highly expressed in the hematopoietic system, while TET3 is overexpressed in germ cells/oocyte, brain tissue and more ubiquitously in somatic cells. TET proteins are responsible for generating all of the 5-hmC in the genome [25], and the loss of TET functions may have dire biological consequences. Numerous loss-of-function mutations of *tet2* have been identified in myeloid cancers where *tet2* has been shown to be a key tumor suppressor. In addition, TET1 has been recently revealed to play an oncogenic role in MLL-rearranged leukemia [26]. Moreover, the loss of 5-hmC has been observed in several malignancies, such as breast cancer [27], liver cancer [28], and kidney cancer [29], and has even been proposed as a prognostic marker in ovarian cancer [30]. However, if TET proteins are capable of oxidizing 5-mC to 5-CaC, the question arises as to why this reaction stops at 5-hmC and why 5-hmC is stable and abundant in the genome. Recent findings of differences among TET proteins suggest that perhaps 5-hmC and other oxidized forms may have epigenetic roles in addition to their function as DNA demethylation intermediates [31-32].

### The mechanism for loss of 5-hmC in cancer

In the past decades, a more comprehensive framework of DNA demethylation has been documented and the loss of methylation has been found to occur by various mechanisms: active loss through iterative oxidation of 5-mC to 5-hmC, 5-fC and 5-CaC by TET proteins followed by excision of 5-fC and 5-CaC by TDG [16]; active loss through deamination of 5-mC to U catalyzed by AID and APOBEC1 followed by BER [33]; passive loss whereby methylation is diluted during several division cycles due to lack of maintenance activity by DNMT1 and ubiquitin-like proteins containing PHD and RING finger domains 1 (UHRF1), and a RING finger-associated mammalian SRA (SET- and RING-associated) domain protein that is required to maintain 5-mC in the CG context [34]. UHRF1 SRA specifically recognizes hemi-5-mCG sites [35], which are the products of semi-conservative DNA replication. In addition, by recruiting maintenance DNMT1, UHRF1 SRA facilitates the restoration of hemi-5-mCG to full-5-mCG after each round of DNA replication in mammals [36]. In the current understanding,

passive demethylation is the dominant mechanism for demethylation of the genome, combined with active removal of 5-mC by TET proteins and replicative loss of both 5-mC and 5-hmC [37-40]. Loss of 5-hmC in tumors occurs through two mechanisms: inactivating mutations of *Tet* and inhibition of TET activity by isocitrate dehydrogenase 1/2 (IDH1/2) mutations [41-45], and these mutations are common in leukemia rather than in solid cancers. Only one study revealed that *Dnmt1* mutations [46] and the resultant losses of substrates of 5-mC are not key players in tumorigenesis.

### Abnormal 5-mC level and regulated genes in melanoma

In previous studies, global DNA hypomethylation was observed in the neoplastic progression of carcinogenesis [47-48]. One hypothesis is that hypomethylation allows previously neoplastic cells to proliferate and eventually metastasize as well as to exert a survival advantage [49]. Moreover, DNA hypomethylation in or around centromeric repeats and other repetitive sequences has been observed to be associated with chromosomal instability [50]. On the other hand, DNA hypermethylation of CpG islands at promoter sites is believed to contribute to tumorigenesis by silencing tumor suppressor genes [17]. Numerous tumor suppressor genes, which are hypermethylated and involved in biological processes, including cell cycle regulation, DNA repair, cell signaling, transcription and apoptosis, have been reported in melanoma (Table 1). Furthermore, the tendency towards hypermethylation has been termed the 'CpG island methylator phenotype' (CIMP) [51-52].

Apart from CDKN2A, RAR-b2, RASSF1A and IDH1, which have been intensively discussed in other reviews [49, 53], the hypermethylation of other genes has also been linked to melanoma. LINE-1, for example, a transposable element that has been used as a surrogate marker for global methylation in several cancer studies, has been found to be hypermethylated in Brazilian melanoma patients and is suggested to be a biomarker for cutaneous melanoma [54]. LINE-1 methylation status is reported to be associated with cancer risk, whereby both the hypermethylation and hypomethylation status appear to vary between different cancer types [55-57]. In addition, it has been suggested that *Claudin 11* (*CLDN11*) could be a useful epigenetic biomarker for identifying melanoma [58-59]. The Claudin gene family consists of 27 members, which encode membrane proteins of the paracellular tight junction. The locations of metastases have been observed to be significantly correlated with the methylation frequency, indicating that the methylation levels in primary melanoma may contribute to differences in the metastatic capacity of melanomas. It would be interesting to analyze the functional alteration by *CLDN11* inactivation in greater detail. Moreover, the methylation status of *MGMT*, which

**Table 1: The hypermethylated genes in melanoma**

<b>Gene</b>	<b>Relevance to melanoma</b>	<b>Ref</b>
<i>LINE-1</i>	Associated with metastasis	[54]
<i>CLDN11</i>	Inactivation of tumor related gene	[58-59]
<i>TERT, MGMT, KIT, TNF, MITF</i>	Associated with clinical characteristics	[63]
<i>RASSF6, RASSF10</i>	Observed in metastatic melanoma and inhibits invasion in melanoma cells	[92-93]
<i>GPX3</i>	Related to the pathogenesis of MM	[94]
<i>MMP-9</i>	Overexpression of MMP9 in MM	[95]
<i>SYNPO2</i>	Decreased expression in MM	[96]
<i>CDKN1C</i>	Arrests cell cycle in G1 by inhibiting G1 cyclin-CDK	[97-98]
<i>LXN</i>	Inhibition of cell proliferation	[97]
<i>WFDC1, SYK, QPCT, PCSK, MFAP2, etc</i>	Unknown	[97]
<i>ASC/PYCARD/ PYCARD</i>	Inhibition of tumorigenesis by reducing IKK $\alpha/\beta$ phosphorylation	[99]
<i>Col11A1</i>	Promotion of tumor aggressive via TGF- $\beta$ 1-MMP3	
<i>SOCS1</i>	Reduction of cytokine-induced effects; Blockade of G1/S and M phase; Association with CDH1	[100]
<i>ZFYVE28, ZBTB47, etc</i>	Unknown	[100]
<i>Caspase 8</i>	Linked to cadmium-stimulated cell growth and inhibition of death pathway	[101]
<i>CDH1</i>	A cell adhesion molecules; loss correlates with high tumor grade and poor prognosis	[102-103]
<i>MGMT</i>	Renders cancer cells resistant	[102]
<i>RAR-b2</i>	Tumor suppressor gene	[102]
<i>CIITA-PIV</i>	Acts on IFN- $\gamma$ pathway	[103]
<i>SOCS2</i>	Attenuates cytokine-induced effects	[103]
<i>TNFRSF10C (DcR1/2)</i>	Decoy receptor that protects cells from TRAIL-mediated apoptosis	[103]
<i>TPM1</i>	Control of actin-mediated cell motility	[103]
<i>TIMP3</i>	Dominant negative regulator of angiogenesis	[103-104]
<i>CDKN2A</i>	Arrests cell cycle in G1 by inhibiting CDK4 and CKD6 and activating pR8	[105]
<i>DPPIV</i>	Decline in serum from melanoma patients	[106-107]
<i>FRZB</i>	A metastasis suppressor; inhibits Wnt5a signaling	[108-109]
<i>SOCS3</i>	Inhibits IL-17/Stat3 pathway; suppresses tumor growth in mouse mode	[110-111]
<i>THBS1</i>	Mediates cell-to-cell and cell-to-matrix interactions which is important for platelet aggregation and angiogenesis	[112]
<i>TM</i>	Downregulation associated with transformation and progression	[113]



encodes a repair protein by removing alkyl groups from the O6-position of guanine residues and its promoter, has been proposed as a biomarker in glioblastoma [60–61], colorectal cancer [62] and melanoma [63]. In melanoma, epigenetic silencing of this gene has been demonstrated in tumors and serum of patients [63–65], suggesting an important role of *MGMT* in tumor development. *MITF* is another example of a DNA hypermethylated gene, which is a transcription factor that controls cell cycle and melanogenesis genes [66–67]. The hypermethylation of the *MITF* promoter has been reported in peripheral blood of melanoma patients who develop more than one lesion, and the *MITF* gene has been observed to be hypermethylated in primary tumors compared to metastatic tumors. Interestingly, the expression of *MITF* varies intratumorally and among different melanoma specimens [68], with high expressions being associated with active differentiation or proliferation and relatively low expressions indicating invasion capacity [69]; these findings suggest that high methylation levels at the *MITF* promoter might be associated with a more aggressive disease and that the higher methylation levels at the *MITF* gene of primary tumors compared to metastatic tumors have a role in controlling the cell cycle. However, more studies are needed to further clarify the functional alterations and roles of hypermethylated genes observed in melanoma.

### Abnormal 5-hmC level and regulated genes in melanoma

As the global hypomethylation marker within the bulk of the genome, the loss of 5-hmC has been observed and used as a biomarker to distinguish melanomas from physiological melanocytes and benign melanocytic proliferations [70]. In the same study, a strong correlation between the loss of 5-hmC and poor prognosis in melanoma has been identified, suggesting 5-hmC level as a potential biomarker with predictive value. Other studies, conducted in the subsequent years, have confirmed this finding [71–75]. Based on this phenomenon, a principle question arises as to the loss of 5-hmC being the cause or consequence of melanoma. Another question is regarding the unknown mechanism of the loss of 5-hmC in melanoma. Although reduced levels of IDH2 and TET proteins have been observed in melanoma, the upstream modulation and consequences of this alteration are still unclear. Targeting TET proteins has been suggested to be a therapeutic strategy in cancer [76]. However, due to the overall hypomethylation levels in melanoma, it is unclear whether TET proteins may act as a cure or a killer.

Notably, the studies mentioned above are focused on the 5-hmC levels in the whole melanoma skin lesion, rather than specifically in melanocytes, which means the tumor infiltrating immune cells may also be included. In our previous study, the infiltrating CD8+ and CD4+ T cells were 20-50% of the total cells under the microscope, and the 5-hmC levels were lost in the T cells (unpublished

data). As is well known, T cells play a critical role in the anti-tumor immune responses. Furthermore, it is a well-accepted notion that cancer cells, such as malignant melanocytes express high levels of PD-L1, which can help cancer cells escape from the PD-1-expressing T cells [77–83]. The questions arise as to whether there is a relationship between high levels of PD-1 and loss of 5-hmC in T cells and whether the loss of 5-hmC contributes to the reduced cytotoxicity of CD8+ T cells in melanoma. Indeed, loss of 5-hmC in the promoter region of *Pdcd-1* has been reported to contribute to the lasting PD-1 expression in T cells in a peptide immunotherapy (PIT) mouse model [84], suggesting a possible role of 5-hmC in PD-1 expression. However, *Pdcd-1* is just one example of a melanoma-related gene; little is known about the involvement of other genes, such as perforins, which are DNA methylation-sensitive genes and have been observed to be hypomethylated in autoimmune diseases in our previous studies [85–86]. In addition, high levels of 5-hmC have been observed in lupus T cells [87], which are the hyper-activated T cells in contrast to tumor infiltrating T cells [8]. Therefore, further investigation into the epigenetic modifications of tumor infiltrating T cells may shed light on the pathogenesis of melanoma and other cancers and provide novel therapeutic strategies.

### Epigenetic biomarkers and therapies in melanoma

As mentioned above, the methylation levels in the promoters of *LINE-1*, *TERT*, *MGMT*, *KIT*, *TNF*, *MITF* [54, 63], among others., and especially the loss of 5-hmC by immunohistochemistry, have the potential to be used as biomarkers to aid in distinguishing malignant melanocytic lesions from dysplastic or borderline melanocytic lesions [70]. The loss of 5-hmC provides a simple and fast method for diagnosis, and it has been recapitulated in other human tumors.

With the reversible advantage, several epigenetic therapies have been approved by the FDA. Azacitidine (Vidaza™) and Decitabine (Dacogen®), which are the DNMT-1 inhibitors, have been approved for treating myelodysplastic syndromes; the drugs are still in clinical trial for melanoma treatment [49]. However, the sole use of DNMT inhibitors in melanoma treatment has yielded mixed results, which might be due to the heterogeneity of tumors and the overall epigenetic alterations. Moreover, reduced expression of TET2 in melanoma may provide novel options [88–89]. As discussed above, the DNA methylation status has been observed to be low in the neoplastic progression of carcinogenesis. Therefore, gene specific modification should be considered for future application. As the Crisper-Cas9 technique is in its blooming era, genetic and epigenetic therapy may benefit from this gene editing revolution. Furthermore, the DNA methylation levels in tumor infiltrating T cells may also provide novel strategies for treatments.

## PERSPECTIVES

Despite the developments in chemotherapy and genetic therapies, poor prognosis of metastatic melanoma and increasing incidence of this malignant disease demands novel and quick strategies for earlier diagnosis and personalized therapies with higher efficacy. In addition to DNA methylation, other epigenetic modifications, such as histone modification and non-coding RNAs, as well as the interplay of these modifications, should be intensively studied for a better understanding of the pathogenesis of melanoma. The varying levels of microRNAs have been observed to be one of the consequences of DNA methylation in cancers [90–91]. Epigenetic alterations may also promote genetic mutations and genomic rearrangements in cancer, though the underlying mechanisms remain unclear. The tumor microenvironment, which might contribute to the unique phenomenon of loss of 5-hmC in melanoma, should be investigated further to improve the current understanding, which may have immense translational implications for benefiting patients afflicted with advanced melanoma and other cancers.

### Author contributions

Siqi Fu and Haijing Wu wrote the manuscript. Huiming Zhang edited the manuscript, and Christina G Lian and Qianjin Lu revised the manuscript.

## CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

## ACKNOWLEDGMENTS

This work was supported by the National Natural Science Foundation of China (No.81220108017, No.81522038, No. 81602767 and No.81430074) and the Programs of Science-Technology Commission of Human Province (2013F J4202) and the Natural Key Clinical Specialty Construction Project of National Health and Family Planning Commission of the People's Republic of China.

## REFERENCES

1. Raimondi S, Sera F, Gandini S, Iodice S, Caini S, Maisonneuve P, Fargnoli MC. MC1R variants, melanoma and red hair color phenotype: a meta-analysis. *Int J Cancer*. 2008; 122: 2753-60.
2. Pfeifer GP. How the environment shapes cancer genomes. *Curr Opin Oncol*. 2015; 27: 71-7.
3. Hernando B, Ibarrola-Villava M, Fernandez LP, Pena-Chilet M, Llorca-Cardenosa M, Oltra SS, Alonso S, Boyano MD, Martinez-Cadenas C, Ribas G. Sex-specific genetic effects associated with pigmentation, sensitivity to sunlight, and melanoma in a population of Spanish origin. *Biol Sex Differ*. 2016; 7: 17.
4. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, Varela I, Lin ML, Ordóñez GR, Bignell GR, Ye K, Alipaz J, Bauer MJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. *Nature*. 2010; 463: 191-6.
5. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, et al. A landscape of driver mutations in melanoma. *Cell*. 2012; 150: 251-63.
6. Bruno W, Martinuzzi C, Andreotti V, Pastorino L, Spagnolo F, Dalmaso B, Cabiddu F, Gualco M, Ballestrero A, Bianchi-Scarra G, Queirolo P, Grillo F, Mastracci L, et al. Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry. *Oncotarget*. 2017;8:8069-8082. doi: 10.18632/oncotarget.14094.
7. Manzano JL, Layos L, Buges C, de Los Llanos Gil M, Vila L, Martinez-Balibrea E, Martinez-Cardus A. Resistant mechanisms to BRAF inhibitors in melanoma. *Ann Transl Med*. 2016; 4: 237.
8. Wu H, Zhao M, Tan L, Lu Q. The key culprit in the pathogenesis of systemic lupus erythematosus: Aberrant DNA methylation. *Autoimmun Rev*. 2016; 15: 684-9.
9. Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. *Cell*. 2007; 128: 669-81.
10. Straussman R, Nejman D, Roberts D, Steinfeld I, Blum B, Benvenisty N, Simon I, Yakhini Z, Cedar H. Developmental programming of CpG island methylation profiles in the human genome. *Nat Struct Mol Biol*. 2009; 16: 564-71.
11. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. *Hum Mol Genet*. 2007; 16 Spec No 1: R50-9.
12. Kuroda A, Rauch TA, Todorov I, Ku HT, Al-Abdullah IH, Kandeel F, Mullen Y, Pfeifer GP, Ferreri K. Insulin gene expression is regulated by DNA methylation. *PLoS One*. 2009; 4: e6953.
13. Doi A, Park IH, Wen B, Murakami P, Aryee MJ, Irizarry R, Herb B, Ladd-Acosta C, Rho J, Loewer S, Miller J, Schlaeger T, Daley GQ, et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. *Nat Genet*. 2009; 41: 1350-3.
14. Bird A. DNA methylation patterns and epigenetic memory. *Genes Dev*. 2002; 16: 6-21.
15. Denis H, Ndlovu MN, Fuks F. Regulation of mammalian DNA methyltransferases: a route to new mechanisms. *EMBO Rep*. 2011; 12: 647-56.
16. Kohli RM, Zhang Y. TET enzymes, TDG and the dynamics of DNA demethylation. *Nature*. 2013; 502: 472-9.
17. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind

- L, Rao A. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. *Science*. 2009; 324: 930-5.
18. Cortellino S, Xu J, Sannai M, Moore R, Caretti E, Cigliano A, Le Coz M, Devarajan K, Wessels A, Soprano D, Abramowitz LK, Bartolomei MS, Rambow F, et al. Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. *Cell*. 2011; 146: 67-79.
  19. He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q, Ding J, Jia Y, Chen Z, Li L, Sun Y, Li X, Dai Q, et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian. *DNA Science*. 2011; 333: 1303-7.
  20. Haffner MC, Chau A, Meeker AK, Esopi DM, Gerber J, Pellakuru LG, Toubaji A, Argani P, Iacobuzio-Donahue C, Nelson WG, Netto GJ, De Marzo AM, Yegnasubramanian S. Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. *Oncotarget*. 2011; 2: 627-37. doi: 10.18632/oncotarget.316.
  21. Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, He C, Zhang Y. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. *Science*. 2011; 333: 1300-3.
  22. Maiti A, Drohat AC. Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-carboxylcytosine: potential implications for active demethylation of CpG sites. *J Biol Chem*. 2011; 286: 35334-8.
  23. Globisch D, Munzel M, Muller M, Michalakis S, Wagner M, Koch S, Bruckl T, Biel M, Carell T. Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates. *PLoS One*. 2010; 5: e15367.
  24. Szwagierczak A, Bultmann S, Schmidt CS, Spada F, Leonhardt H. Sensitive enzymatic quantification of 5-hydroxymethylcytosine in genomic DNA. *Nucleic Acids Res*. 2010; 38: e181.
  25. Koh KP, Yabuuchi A, Rao S, Huang Y, Cunniff K, Nardone J, Laiho A, Tahiliani M, Sommer CA, Mostoslavsky G, Lahesmaa R, Orkin SH, Rodig SJ, et al. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. *Cell Stem Cell*. 2011; 8: 200-13.
  26. Huang H, Jiang X, Li Z, Li Y, Song CX, He C, Sun M, Chen P, Gurbuxani S, Wang J, Hong GM, Elkahloun AG, Arnovitz S, et al. TET1 plays an essential oncogenic role in MLL-rearranged leukemia. *Proc Natl Acad Sci U S A*. 2013; 110: 11994-9.
  27. Sun M, Song CX, Huang H, Frankenberger CA, Sankarasharma D, Gomes S, Chen P, Chen J, Chada KK, He C, Rosner MR. HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. *Proc Natl Acad Sci U S A*. 2013; 110: 9920-5.
  28. Thomson JP, Ottaviano R, Unterberger EB, Lempiainen H, Muller A, Terranova R, Illingworth RS, Webb S, Kerr AR, Lyall MJ, Drake AJ, Wolf CR, Moggs JG, et al. Loss of Tet1-Associated 5-Hydroxymethylcytosine Is Concomitant with Aberrant Promoter Hypermethylation in Liver Cancer. *Cancer Res*. 2016; 76: 3097-108.
  29. Chen K, Zhang J, Guo Z, Ma Q, Xu Z, Zhou Y, Xu Z, Li Z, Liu Y, Ye X, Li X, Yuan B, Ke Y, et al. Loss of 5-hydroxymethylcytosine is linked to gene body hypermethylation in kidney cancer. *Cell Res*. 2016; 26: 103-18.
  30. Zhang LY, Li PL, Wang TZ, Zhang XC. Prognostic values of 5-hmC, 5-mC and TET2 in epithelial ovarian cancer. *Arch Gynecol Obstet*. 2015; 292: 891-7.
  31. Ko M, An J, Bandukwala HS, Chavez L, Aijo T, Pastor WA, Segal MF, Li H, Koh KP, Lahdesmaki H, Hogan PG, Aravind L, Rao A. Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. *Nature*. 2013; 497: 122-6.
  32. Huang Y, Chavez L, Chang X, Wang X, Pastor WA, Kang J, Zepeda-Martinez JA, Pape UJ, Jacobsen SE, Peters B, Rao A. Distinct roles of the methylcytosine oxidases Tet1 and Tet2 in mouse embryonic stem cells. *Proc Natl Acad Sci U S A*. 2014; 111: 1361-6.
  33. Seisenberger S, Peat JR, Reik W. Conceptual links between DNA methylation reprogramming in the early embryo and primordial germ cells. *Curr Opin Cell Biol*. 2013; 25: 281-8.
  34. Bostick M, Kim JK, Esteve PO, Clark A, Pradhan S, Jacobsen SE. UHRF1 plays a role in maintaining DNA methylation in mammalian cells. *Science*. 2007; 317: 1760-4.
  35. Arita K, Ariyoshi M, Tochio H, Nakamura Y, Shirakawa M. Recognition of hemi-methylated DNA by the SRA protein UHRF1 by a base-flipping mechanism. *Nature*. 2008; 455: 818-21.
  36. Sharif J, Muto M, Takebayashi S, Suetake I, Iwamatsu A, Endo TA, Shinga J, Mizutani-Koseki Y, Toyoda T, Okamura K, Tajima S, Mitsuya K, Okano M, et al. The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. *Nature*. 2007; 450: 908-12.
  37. Xiong J, Zhang Z, Chen J, Huang H, Xu Y, Ding X, Zheng Y, Nishinakamura R, Xu GL, Wang H, Chen S, Gao S, Zhu B. Cooperative Action between SALL4A and TET Proteins in Stepwise Oxidation of 5-Methylcytosine. *Mol Cell*. 2016; 64: 913-925.
  38. Yin X, Xu Y. Structure and Function of TET Enzymes. *Adv Exp Med Biol*. 2016; 945: 275-302.
  39. Vincent JJ, Huang Y, Chen PY, Feng S, Calvopina JH, Nee K, Lee SA, Le T, Yoon AJ, Faull K, Fan G, Rao A, Jacobsen SE, et al. Stage-specific roles for tet1 and tet2 in DNA demethylation in primordial germ cells. *Cell Stem Cell*. 2013; 12: 470-8.



40. Okashita N, Kumaki Y, Ebi K, Nishi M, Okamoto Y, Nakayama M, Hashimoto S, Nakamura T, Sugawara K, Kojima N, Takada T, Okano M, Seki Y. PRDM14 promotes active DNA demethylation through the ten-eleven translocation (TET)-mediated base excision repair pathway in embryonic stem cells. *Development*. 2014; 141: 269-80.
41. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. *Cancer Cell*. 2010; 18: 553-67.
42. IDH1 Mutations Can Drive AML through TET2-Independent Mechanisms. *Cancer Discov*. 2016; 6: 941.
43. Chiba S. Significance of TET2 mutations in myeloid and lymphoid neoplasms *Rinsho Ketsueki*. 2016; 57: 715-22.
44. Inoue S, Lemonnier F, Mak TW. Roles of IDH1/2 and TET2 mutations in myeloid disorders. *Int J Hematol*. 2016; 103: 627-33.
45. Liu MY, Torabifard H, Crawford DJ, DeNizio JE, Cao XJ, Garcia BA, Cisneros GA, Kohli RM. Mutations along a TET2 active site scaffold stall oxidation at 5-hydroxymethylcytosine. *Nat Chem Biol*. 2017; 13: 181-187.
46. Kanai Y, Ushijima S, Nakanishi Y, Sakamoto M, Hirohashi S. Mutation of the DNA methyltransferase (DNMT) 1 gene in human colorectal cancers. *Cancer Lett*. 2003; 192: 75-82.
47. Kim YI, Giuliano A, Hatch KD, Schneider A, Nour MA, Dallal GE, Selhub J, Mason JB. Global DNA hypomethylation increases progressively in cervical dysplasia and carcinoma. *Cancer*. 1994; 74: 893-9.
48. Cravo M, Pinto R, Fidalgo P, Chaves P, Gloria L, Nobre-Leitao C, Costa Mira F. Global DNA hypomethylation occurs in the early stages of intestinal type gastric carcinoma. *Gut*. 1996; 39: 434-8.
49. Lee JJ, Murphy GF, Lian CG. Melanoma epigenetics: novel mechanisms, markers, and medicines. *Lab Invest*. 2014; 94: 822-38.
50. Karpf AR, Matsui S. Genetic disruption of cytosine DNA methyltransferase enzymes induces chromosomal instability in human cancer cells. *Cancer Res*. 2005; 65: 8635-9.
51. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. *Proc Natl Acad Sci U S A*. 1999; 96: 8681-6.
52. Tanemura A, Terando AM, Sim MS, van Hoesel AQ, de Maat MF, Morton DL, Hoon DS. CpG island methylator phenotype predicts progression of malignant melanoma. *Clin Cancer Res*. 2009; 15: 1801-7.
53. Sarkar D, Leung EY, Baguley BC, Finlay GJ, Askarian-Amiri ME. Epigenetic regulation in human melanoma: past and future. *Epigenetics*. 2015; 10: 103-21.
54. De Araujo ES, Kashiwabara AY, Achatz MI, Moredo LF, De Sa BC, Duprat JP, Rosenberg C, Carraro DM, Krepischi AC. LINE-1 hypermethylation in peripheral blood of cutaneous melanoma patients is associated with metastasis *Melanoma Res*. 2015; 25: 173-7.
55. Di JZ, Han XD, Gu WY, Wang Y, Zheng Q, Zhang P, Wu HM, Zhu ZZ. Association of hypomethylation of LINE-1 repetitive element in blood leukocyte DNA with an increased risk of hepatocellular carcinoma. *J Zhejiang Univ Sci B*. 2011; 12: 805-11.
56. Liao LM, Brennan P, van Bommel DM, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Rothman N, Boffetta P, et al. LINE-1 methylation levels in leukocyte DNA and risk of renal cell cancer. *PLoS One*. 2011; 6: e27361.
57. Hou L, Wang H, Sartori S, Gawron A, Lissowska J, Bollati V, Tarantini L, Zhang FF, Zatonski W, Chow WH, Baccarelli A. Blood leukocyte DNA hypomethylation and gastric cancer risk in a high-risk Polish population. *Int J Cancer*. 2010; 127: 1866-74.
58. Walesch SK, Richter AM, Helmbold P, Dammann RH. Claudin11 Promoter Hypermethylation Is Frequent in Malignant Melanoma of the Skin, but Uncommon in Nevus Cell Nevi. *Cancers (Basel)*. 2015; 7: 1233-43.
59. Gao L, van den Hurk K, Moerkerk PT, Goeman JJ, Beck S, Gruis NA, van den Oord JJ, Winnepeninckx VJ, van Engeland M, and van Doorn R. Promoter CpG island hypermethylation in dysplastic nevus and melanoma: CLDN11 as an epigenetic biomarker for malignancy. *J Invest Dermatol*. 2014; 134: 2957-66.
60. Cankovic M, Nikiforova MN, Snuderl M, Adesina AM, Lindeman N, Wen PY, Lee EQ. The role of MGMT testing in clinical practice: a report of the association for molecular pathology. *J Mol Diagn*. 2013; 15: 539-55.
61. Kim DC, Kim KU, Kim YZ. Prognostic Role of Methylation Status of the MGMT Promoter Determined Quantitatively by Pyrosequencing in Glioblastoma Patients. *J Korean Neurosurg Soc*. 2016; 59: 26-36.
62. Inno A, Fanetti G, Di Bartolomeo M, Gori S, Maggi C, Cirillo M, Iacovelli R, Nichetti F, Martinetti A, de Braud F, Bossi I, Pietrantonio F. Role of MGMT as biomarker in colorectal cancer. *World J Clin Cases*. 2014; 2: 835-9.
63. de Araujo ES, Pramio DT, Kashiwabara AY, Pennacchi PC, Maria-Engler SS, Achatz MI, Campos AH, Duprat JP, Rosenberg C, Carraro DM, Krepischi AC. DNA Methylation Levels of Melanoma Risk Genes Are Associated with Clinical Characteristics of Melanoma. *Patients Biomed Res Int*. 2015; 2015: 376423.
64. Marini A, Mirmohammadsadegh A, Nambiar S, Gustrau A, Ruzicka T, Hengge UR. Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma. *J Invest Dermatol*. 2006; 126: 422-31.
65. Rastetter M, Schagdarsurengin U, Lahtz C, Fiedler E, Marsch W, Dammann R, Helmbold P. Frequent intra-tumoural heterogeneity of promoter hypermethylation in malignant melanoma. *Histol Histopathol*. 2007; 22: 1005-15.

66. Cheli Y, Ohanna M, Ballotti R, Bertolotto C. Fifteen-year quest for microphthalmia-associated transcription factor target genes. *Pigment Cell Melanoma Res.* 2010; 23: 27-40.
67. Law MH, Macgregor S, Hayward NK. Melanoma genetics: recent findings take us beyond well-traveled pathways. *J Invest Dermatol.* 2012; 132: 1763-74.
68. Ennen M, Keime C, Kobi D, Mengus G, Lipsker D, Thibault-Carpentier C, Davidson I. Single-cell gene expression signatures reveal melanoma cell heterogeneity. *Oncogene.* 2015; 34: 3251-63.
69. Hartman ML, Czyz M. MITF in melanoma: mechanisms behind its expression and activity. *Cell Mol Life Sci.* 2015; 72: 1249-60.
70. Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, Xu W, Tan L, Hu Y, Zhan Q, Lee CW, Hu D, Lian BQ, et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. *Cell.* 2012; 150: 1135-46.
71. Gambichler T, Sand M, Skrygan M. Loss of 5-hydroxymethylcytosine and ten-eleven translocation 2 protein expression in malignant melanoma. *Melanoma Res.* 2013; 23: 218-20.
72. Lee JJ, Cook M, Mihm MC, Xu S, Zhan Q, Wang TJ, Murphy GF, Lian CG. Loss of the epigenetic mark, 5-Hydroxymethylcytosine, correlates with small cell/nevoid subpopulations and assists in microstaging of human melanoma. *Oncotarget.* 2015; 6: 37995-8004. doi: 10.18632/oncotarget.6062.
73. Lee JJ, Granter SR, Laga AC, Saavedra AP, Zhan Q, Guo W, Xu S, Murphy GF, Lian CG. 5-Hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in sentinel lymph node biopsies. *Mod Pathol.* 2015; 28: 218-29.
74. Pavlova O, Fraitag S, Hohl D. 5-Hydroxymethylcytosine Expression in Proliferative Nodules Arising within Congenital Nevi Allows Differentiation from Malignant Melanoma. *J Invest Dermatol.* 2016; 136: 2453-2461.
75. Saldanha G, Joshi K, Lawes K, Bamford M, Moosa F, Teo KW, Pringle JH. 5-Hydroxymethylcytosine is an independent predictor of survival in malignant melanoma. *Mod Pathol.* 2017; 30: 60-68.
76. Thienpont B, Galle E, Lambrechts D. TET enzymes as oxygen-dependent tumor suppressors: exciting new avenues for cancer management. *Epigenomics.* 2016; 8: 1445-1448.
77. Abdel-Rahman O. PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis. *Immunotherapy.* 2016; 8: 1081-9.
78. Contreras-Sandoval AM, Merino M, Vasquez M, Troconiz IF, Berraondo P, Garrido MJ. Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model. *Oncotarget.* 2016; 7: 76891-76901. doi: 10.18632/oncotarget.12727.
79. Gentzler R, Hall R, Kunk PR, Gaughan E, Dillon P, Slingluff CL Jr, Rahma OE. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. *Immunotherapy.* 2016; 8: 583-600.
80. Lee J, Kefford R, Carlino M. PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges. *Immunotherapy.* 2016; 8: 733-46.
81. Loo K, Daud A. Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma. *Immunotherapy.* 2016; 8: 775-84.
82. Madore J, Strbenac D, Vilain R, Menzies AM, Yang JY, Thompson JF, Long GV, Mann GJ, Scolyer RA, Wilmott JS. PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma. *Clin Cancer Res.* 2016; 22: 3915-23.
83. Obeid JM, Erdag G, Smolkin ME, Deacon DH, Patterson JW, Chen L, Bullock TN, Slingluff CL. PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome. *Oncoimmunology.* 2016; 5: e1235107.
84. McPherson RC, Konkel JE, Prendergast CT, Thomson JP, Ottaviano R, Leech MD, Kay O, Zandee SE, Sweeney CH, Wraith DC, Meehan RR, Drake AJ, Anderton SM. Epigenetic modification of the PD-1 (*Pdcd1*) promoter in effector CD4(+) T cells tolerized by peptide immunotherapy. *Elife.* 2014; 3.
85. Lu Q, Wu A, Ray D, Deng C, Attwood J, Hanash S, Pipkin M, Lichtenheld M, Richardson B. DNA methylation and chromatin structure regulate T cell perforin gene expression. *J Immunol.* 2003; 170: 5124-32.
86. Luo Y, Zhang X, Zhao M, Lu Q. DNA demethylation of the perforin promoter in CD4(+) T cells from patients with subacute cutaneous lupus erythematosus. *J Dermatol Sci.* 2009; 56: 33-6.
87. Zhao M, Wang J, Liao W, Li D, Li M, Wu H, Zhang Y, Gershwin ME, Lu Q. Increased 5-hydroxymethylcytosine in CD4(+) T cells in systemic lupus erythematosus. *J Autoimmun.* 2016; 69: 64-73.
88. Gomes CB, Zechin KG, Xu S, Stelini RF, Nishimoto IN, Zhan Q, Xu T, Qin G, Treister NS, Murphy GF, Lian CG. TET2 Negatively Regulates Nestin Expression in Human Melanoma. *Am J Pathol.* 2016; 186: 1427-34.
89. Gong F, Guo Y, Niu Y, Jin J, Zhang X, Shi X, Zhang L, Li R, Chen L, Ma RZ. Epigenetic silencing of TET2 and TET3 induces an EMT-like process in melanoma. *Oncotarget.* 2017; 8: 315-328. doi: 10.18632/oncotarget.13324.
90. Yin H, Song P, Su R, Yang G, Dong L, Luo M, Wang B, Gong B, Liu C, Song W, Wang F, Ma Y, Zhang J, et al. DNA Methylation mediated down-regulating of MicroRNA-33b and its role in gastric cancer. *Sci Rep.* 2016; 6: 18824.
91. Noguchi S, Mori T, Nakagawa T, Itamoto K, Haraguchi T, Mizuno T. DNA methylation contributes toward silencing of antioncogenic microRNA-203 in human and canine melanoma cells. *Melanoma Res.* 2015; 25: 390-8.
92. Mezzanotte JJ, Hill V, Schmidt ML, Shinawi T, Tommasi S, Krex D, Schackert G, Pfeifer GP, Latif F, Clark GJ. RASSF6 exhibits promoter hypermethylation in metastatic

- melanoma and inhibits invasion in melanoma cells. *Epigenetics*. 2014; 9: 1496-503.
93. Helmbold P, Richter AM, Walesch S, Skorokhod A, Marsch W, Enk A, Dammann RH. RASSF10 promoter hypermethylation is frequent in malignant melanoma of the skin but uncommon in nevus cell nevi. *J Invest Dermatol*. 2012; 132: 687-94.
  94. Chen H, Zheng Z, Kim KY, Jin X, Roh MR, Jin Z. Hypermethylation and downregulation of glutathione peroxidase 3 are related to pathogenesis of melanoma. *Oncol Rep*. 2016; 36: 2737-2744.
  95. Falzone L, Salemi R, Travali S, Scalisi A, McCubrey JA, Candido S, Libra M. MMP-9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma. *Aging (Albany NY)*. 2016; 8: 933-44. doi: 10.18632/aging.100951.
  96. Gao L, van den Hurk K, Nsengimana J, Laye JP, van den Oord JJ, Beck S, Gruis NA, Zoutman WH, van Engeland M, Newton-Bishop JA, Winnepenninckx VJ, and van Doorn R. Prognostic Significance of Promoter Hypermethylation and Diminished Gene Expression of SYNPO2 in Melanoma. *J Invest Dermatol*. 2015; 135: 2328-31.
  97. Muthusamy V, Duraisamy S, Bradbury CM, Hobbs C, Curley DP, Nelson B, Bosenberg M. Epigenetic silencing of novel tumor suppressors in malignant melanoma. *Cancer Res*. 2006; 66: 11187-93.
  98. Curry JL, Richards HW, Huttenbach YT, Medrano EE, Reed JA. Different expression patterns of p27 and p57 proteins in benign and malignant melanocytic neoplasms and in cultured human melanocytes. *J Cutan Pathol*. 2009; 36: 197-205.
  99. Liu W, Luo Y, Dunn JH, Norris DA, Dinarello CA, Fujita M. Dual role of apoptosis-associated speck-like protein containing a CARD (ASC) in tumorigenesis of human melanoma. *J Invest Dermatol*. 2013; 133: 518-27.
  100. Koga Y, Pelizzola M, Cheng E, Krauthammer M, Sznol M, Ariyan S, Narayan D, Molinaro AM, Halaban R, Weissman SM. Genome-wide screen of promoter methylation identifies novel markers in melanoma. *Genome Res*. 2009; 19: 1462-70.
  101. Venza M, Visalli M, Biondo C, Oteri R, Agliano F, Morabito S, Teti D, Venza I. Epigenetic marks responsible for cadmium-induced melanoma cell overgrowth. *Toxicol In Vitro*. 2015; 29: 242-50.
  102. Furuta J, Umehayashi Y, Miyamoto K, Kikuchi K, Otsuka F, Sugimura T, Ushijima T. Promoter methylation profiling of 30 genes in human malignant melanoma. *Cancer Sci*. 2004; 95: 962-8.
  103. Liu S, Ren S, Howell P, Fodstad O, Riker AI. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. *Pigment Cell Melanoma Res*. 2008; 21: 545-58.
  104. Das AM, Seynhaeve AL, Rens JA, Vermeulen CE, Koning GA, Eggermont AM, Ten Hagen TL. Differential TIMP3 expression affects tumor progression and angiogenesis in melanomas through regulation of directionally persistent endothelial cell migration. *Angiogenesis*. 2014; 17: 163-77.
  105. Schinke C, Mo Y, Yu Y, Amiri K, Sosman J, Grealley J, Verma A. Aberrant DNA methylation in malignant melanoma. *Melanoma Res*. 2010; 20: 253-65.
  106. McGuinness C, Wesley UV. Dipeptidyl peptidase IV (DPPIV), a candidate tumor suppressor gene in melanomas is silenced by promoter methylation. *Front Biosci*. 2008; 13: 2435-43.
  107. Matic IZ, Ethordic M, Grozdanic N, Damjanovic A, Kolundzija B, Eric-Nikolic A, Dzodic R, Sasic M, Nikolic S, Dobrosavljevic D, Raskovic S, Andrejevic S, Gavrilovic D, et al. Serum activity of DPPIV and its expression on lymphocytes in patients with melanoma and in people with vitiligo. *BMC Immunol*. 2012; 13: 48.
  108. Conway K, Edmiston SN, Khondker ZS, Groben PA, Zhou X, Chu H, Kuan PF, Hao H, Carson C, Berwick M, Olilla DW, Thomas NE. DNA-methylation profiling distinguishes malignant melanomas from benign nevi. *Pigment Cell Melanoma Res*. 2011; 24: 352-60.
  109. Ekstrom EJ, Sherwood V, Andersson T. Methylation and loss of Secreted Frizzled-Related Protein 3 enhances melanoma cell migration and invasion. *PLoS One*. 2011; 6: e18674.
  110. Tokita T, Maesawa C, Kimura T, Kotani K, Takahashi K, Akasaka T, Masuda T. Methylation status of the SOCS3 gene in human malignant melanomas. *Int J Oncol*. 2007; 30: 689-94.
  111. Fang S, Liu B, Sun Q, Zhao J, Qi H, Li Q. Platelet factor 4 inhibits IL-17/Stat3 pathway via upregulation of SOCS3 expression in melanoma Inflammation. 2014; 37: 1744-50.
  112. Bonazzi VF, Nancarrow DJ, Stark MS, Moser RJ, Boyle GM, Aoude LG, Schmidt C, Hayward NK. Cross-platform array screening identifies COL1A2, THBS1, TNFRSF10D and UCHL1 as genes frequently silenced by methylation in melanoma. *PLoS One*. 2011; 6: e26121.
  113. Furuta J, Kaneda A, Umehayashi Y, Otsuka F, Sugimura T, Ushijima T. Silencing of the thrombomodulin gene in human malignant melanoma. *Melanoma Res*. 2005; 15: 15-20.